INTRODUCTION {#s1}
============

Orofacial clefts include cleft palate only (CPO), cleft lip with cleft palate (CLP) and cleft lip only (CLO). Approximately 1/800 live births worldwide are affected by these diseases \[[@R1]\]. Nonsyndromic orofacial clefts occur as isolated entities with no other apparent structural and/or developmental abnormalities. The majority of CLP cases are nonsyndromic (NS) (∼70%) \[[@R2]\]. Cleft palate only (CPO) is the least common form of the orofacial clefts (approximately 33%) \[[@R3]\]. The aetiology is multifactorial and involves both genetic and environmental risk factors. Most studies suggest that distinct etiological mechanisms underlie CLP and CPO \[[@R4], [@R5]\]; however, some overlapping exists in their aetiologies \[[@R6], [@R7]\]. Thus, our knowledge about whether CPO does indeed differ from CLP remains incomplete.

Mounting evidence suggests that miRNAs could be functionally important for the regulation of vertebrate and mammalian orofacial clefting \[[@R8]--[@R10]\]. The identification of the miRNA-mRNA regulatory molecules is important to understand the regulatory mechanisms of CLP and CPO. The potential of plasma miRNAs to be potential non-invasive diagnostic biomarkers for nonsyndromic cleft lip in infants has been reported \[[@R11]\]. In this study, based on our Agilent human miRNA microarray chips, we identified differentially expressed plasma microRNAs in nonsyndromic cleft palate and nonsyndromic cleft lip with cleft palate. Using gene ontology and pathway analysis of the target genes of these miRNAs, we report that distinct biological processes interact and coordinate the physiology of nonsyndromic cleft palate and nonsyndromic cleft lip with cleft palate.

RESULTS {#s2}
=======

miRNA microarray analysis {#s2_1}
-------------------------

To investigate whether circulating miRNAs are associated with the pathogenesis of cleft palate and cleft lip with cleft palate, plasma samples were collected from healthy children and children with nonsyndromic cleft palate (NSCLP) and cleft lip with cleft palate (NSCLP). A comprehensive miRNA microarray analysis was performed on nine plasma samples, including three NSCP plasma samples (mixed as the CP group), three NSCLP plasma samples (mixed as the CLP group) and three plasma samples from healthy children (mixed as the Control group). Hierarchical clustering was used to show the miRNAs expression variation and patterns among these three groups CP, CLP and Control (Figure [1A](#F1){ref-type="fig"}). We also screened for differentially expressed miRNAs that showed a two-fold or greater change (compared to the control group) in the CP and CLP plasma samples, and illustrated the overlapping between the two data sets using Venn diagrams (Figure [1B, 1C](#F1){ref-type="fig"}). A total of 63 miRNAs were upregulated in both the CP and CLP plasma samples (Figure [1B](#F1){ref-type="fig"}). The upregulated miRNAs are listed in Table [1](#T1){ref-type="table"} (fold change ≥ 2). Furthermore, 49 miRNAs were downregulated in both the CP and CLP plasma samples (Figure [1C](#F1){ref-type="fig"}). The downregulated miRNAs are listed in Table [2](#T2){ref-type="table"} (fold change ≥ 2).

![plasma miRNA microarray expression data among the patients with nonsyndromic cleft palate, nonsyndromic cleft lip with cleft palate and healthy children\
(**A**) Hierarchical clustering reveals the miRNA expression profile. (**B**) Venn diagrams show the number of distinct and overlapping upregulated miRNAs in CP and CLP. (**C**) Venn diagrams show the number of distinct and overlapping downregulated miRNAs in CP and CLP.](oncotarget-07-86266-g001){#F1}

###### List of 63 miRNAs that were co-overexpressed in CP and CLP plasma samples

  miRNA               Fold change in CP   Fold change in CLP   Mirbase_accession_No
  ------------------- ------------------- -------------------- ----------------------
  hsa-let-7a-5p       2.593625            3.62266              MIMAT0000062
  hsa-let-7f-5p       36.22597            94.70817             MIMAT0000067
  hsa-miR-1182        21.12385            26.03614             MIMAT0005827
  hsa-miR-1185-2-3p   35.17025            22.02562             MIMAT0022713
  hsa-miR-1226-5p     33.54898            41.68948             MIMAT0005576
  hsa-miR-1249-3p     40.65461            26.77842             MIMAT0005901
  hsa-miR-126-5p      22.59582            11.5428              MIMAT0000444
  hsa-miR-139-3p      9.764356            30.04384             MIMAT0004552
  hsa-miR-144-5p      22.1287             34.8168              MIMAT0004600
  hsa-miR-150-5p      2.004063            5.130724             MIMAT0000451
  hsa-miR-17-3p       25.74652            10.66161             MIMAT0000071
  hsa-miR-194-5p      2.004321            2.671813             MIMAT0000460
  hsa-miR-195-5p      11.29176            10.05747             MIMAT0000461
  hsa-miR-215-5p      10.32331            24.41001             MIMAT0000272
  hsa-miR-27b-3p      10.79146            4.974262             MIMAT0000419
  hsa-miR-301a-3p     2.216769            2.039103             MIMAT0000688
  hsa-miR-30b-5p      43.5225             53.10868             MIMAT0000420
  hsa-miR-30c-1-3p    9.047681            4.742653             MIMAT0004674
  hsa-miR-30c-5p      10.41076            4.763296             MIMAT0000244
  hsa-miR-3156-5p     39.43275            33.64425             MIMAT0015030
  hsa-miR-3158-5p     36.59335            29.4613              MIMAT0019211
  hsa-miR-340-5p      4.435901            10.44386             MIMAT0004692
  hsa-miR-3648        2.844126            7.529149             MIMAT0018068
  hsa-miR-374a-5p     41.436              53.56016             MIMAT0000727
  hsa-miR-3945        54.65085            55.2666              MIMAT0018361
  hsa-miR-424-5p      11.5428             23.91295             MIMAT0001341
  hsa-miR-4314        48.6155             91.10153             MIMAT0016868
  hsa-miR-4417        39.91649            27.81709             MIMAT0018929
  hsa-miR-4496        21.48931            25.86879             MIMAT0019031
  hsa-miR-4508        20.71299            22.6453              MIMAT0019045
  hsa-miR-4673        23.30205            21.36562             MIMAT0019755
  hsa-miR-4688        9.853577            37.87732             MIMAT0019777
  hsa-miR-4698        2.111651            2.899994             MIMAT0019793
  hsa-miR-4707-3p     53.56016            88.45938             MIMAT0019808
  hsa-miR-4716-3p     25.26925            22.1287              MIMAT0019827
  hsa-miR-4734        10.01005            24.63449             MIMAT0019859
  hsa-miR-4769-5p     10.66161            4.959765             MIMAT0019922
  hsa-miR-532-5p      10.62257            4.541014             MIMAT0002888
  hsa-miR-550a-3-5p   22.36834            10.8752              MIMAT0020925
  hsa-miR-564         9.835221            47.83535             MIMAT0003228
  hsa-miR-601         35.01135            36.03937             MIMAT0003269
  hsa-miR-6071        21.2377             52.38286             MIMAT0023696
  hsa-miR-6133        10.44386            27.50138             MIMAT0024617
  hsa-miR-652-3p      22.6453             4.860917             MIMAT0003322
  hsa-miR-660-5p      24.63449            28.21952             MIMAT0003338
  hsa-miR-663a        28.76448            47.35553             MIMAT0003326
  hsa-miR-6738-5p     9.491392            40.3395              MIMAT0027377
  hsa-miR-6748-5p     10.37443            20.60795             MIMAT0027396
  hsa-miR-6758-5p     23.39996            9.81465              MIMAT0027416
  hsa-miR-6774-5p     20.60795            4.699301             MIMAT0027448
  hsa-miR-6777-3p     35.46738            53.8186              MIMAT0027455
  hsa-miR-6784-5p     33.23554            28.4822              MIMAT0027468
  hsa-miR-6793-5p     23.91295            3.695676             MIMAT0027486
  hsa-miR-6807-5p     27.50138            34.4576              MIMAT0027514
  hsa-miR-6820-5p     22.91788            39.11779             MIMAT0027540
  hsa-miR-6887-5p     28.4822             22.30914             MIMAT0027674
  hsa-miR-6889-5p     9.57147             39.91649             MIMAT0027678
  hsa-miR-7109-5p     22.30914            20.89674             MIMAT0028115
  hsa-miR-711         21.61314            28.39723             MIMAT0012734
  hsa-miR-7114-5p     9.41187             23.30205             MIMAT0028125
  hsa-miR-8060        29.71088            24.85582             MIMAT0030987
  hsa-miR-8089        9.716781            22.36834             MIMAT0031016
  hsa-miR-877-5p      36.42551            38.19915             MIMAT0004949

###### List of 49 miRNAs that were co-downregulated in CP and CLP plasma samples

  miRNA              Fold change in CP   Fold change in CLP   Mirbase_accession_No
  ------------------ ------------------- -------------------- ----------------------
  hsa-miR-122-5p     0.014823713         0.330486             MIMAT0000421
  hsa-miR-1237-3p    0.04279959          0.178651             MIMAT0005592
  hsa-miR-1260a      0.42197306          0.188688             MIMAT0005911
  hsa-miR-1281       0.292045994         0.361803             MIMAT0005939
  hsa-miR-1304-3p    0.022515879         0.021418             MIMAT0022720
  hsa-miR-1825       0.305341608         0.315741             MIMAT0006765
  hsa-miR-191-3p     0.210027916         0.202306             MIMAT0001618
  hsa-miR-193a-5p    0.425119659         0.1725               MIMAT0004614
  hsa-miR-221-3p     0.38537867          0.317683             MIMAT0000278
  hsa-miR-3187-3p    0.013885943         0.013209             MIMAT0015069
  hsa-miR-338-3p     0.04279959          0.214453             MIMAT0000763
  hsa-miR-4286       0.481616926         0.148742             MIMAT0016916
  hsa-miR-4290       0.04279959          0.040714             MIMAT0016921
  hsa-miR-4428       0.354170872         0.170319             MIMAT0018943
  hsa-miR-4433a-5p   0.207866953         0.084119             MIMAT0020956
  hsa-miR-4455       0.422613454         0.365739             MIMAT0018977
  hsa-miR-4649-3p    0.200187171         0.091757             MIMAT0019712
  hsa-miR-4668-5p    0.389545483         0.170031             MIMAT0019745
  hsa-miR-4728-5p    0.471992677         0.412945             MIMAT0019849
  hsa-miR-4738-3p    0.356057291         0.151948             MIMAT0019867
  hsa-miR-4749-3p    0.431131255         0.458677             MIMAT0019886
  hsa-miR-4769-3p    0.299500434         0.328468             MIMAT0019923
  hsa-miR-483-3p     0.025346248         0.25173              MIMAT0002173
  hsa-miR-494-3p     0.421072365         0.074374             MIMAT0002816
  hsa-miR-497-5p     0.26762079          0.401373             MIMAT0002820
  hsa-miR-574-3p     0.032438225         0.165143             MIMAT0003239
  hsa-miR-574-5p     0.398577728         0.302998             MIMAT0004795
  hsa-miR-636        0.405198518         0.173279             MIMAT0003306
  hsa-miR-6508-5p    0.021489753         0.091996             MIMAT0025472
  hsa-miR-6515-3p    0.233030948         0.255185             MIMAT0025487
  hsa-miR-6732-3p    0.029496564         0.129832             MIMAT0027366
  hsa-miR-6751-3p    0.096354218         0.272251             MIMAT0027403
  hsa-miR-6776-5p    0.023690732         0.022536             MIMAT0027452
  hsa-miR-6785-5p    0.292436258         0.215104             MIMAT0027470
  hsa-miR-6797-3p    0.486474133         0.356753             MIMAT0027495
  hsa-miR-6800-3p    0.207096926         0.209525             MIMAT0027501
  hsa-miR-6813-3p    0.295100077         0.244702             MIMAT0027527
  hsa-miR-6851-3p    0.02840522          0.109846             MIMAT0027603
  hsa-miR-6861-3p    0.02773473          0.119237             MIMAT0027624
  hsa-miR-6870-3p    0.04279959          0.040714             MIMAT0027641
  hsa-miR-6873-3p    0.022068915         0.020993             MIMAT0027647
  hsa-miR-6880-3p    0.04279959          0.040714             MIMAT0027661
  hsa-miR-7111-3p    0.02234751          0.227218             MIMAT0028120
  hsa-miR-7114-3p    0.04279959          0.180041             MIMAT0028126
  hsa-miR-7641       0.466679177         0.29544              MIMAT0029782
  hsa-miR-766-3p     0.248388555         0.280315             MIMAT0003888
  hsa-miR-7975       0.443053554         0.153591             MIMAT0031178
  hsa-miR-7977       0.425407891         0.15303              MIMAT0031180
  hsa-miR-8073       0.04279959          0.462327             MIMAT0031000

Expression validation of selected miRNAs using Bulge-Loop™ qRT-PCR analysis {#s2_2}
---------------------------------------------------------------------------

Among the 63 upregulated and 49 downregulated miRNAs in both the CP and CLP plasma samples, six miRNAs, namely miR-340--5p, miR-877--5p, miR-3648, miR-1260a, miR-494--3p, and miR-1304--3p, were selected for expression validation (Table [3](#T3){ref-type="table"}). The selection standards were the same as we previously reported \[[@R11]\] and were as follows: infrequently reported in the literature, present in both samples and higher deep sequencing reads in miRBase. Bulge-Loop™ qRT-PCR was performed to validate these six differentially expressed miRNAs found in the miRNA microarray analysis. RNA was isolated from 57 plasma samples, including samples from 16 CP, 33 CLP and 8 healthy children, using the mirVana PARIS kit (Ambion, Carlsbad, CA, USA). The results showed that three miRNAs, miR-340--5p, miR-877--5p and miR-3648, were significantly upregulated in both the CP and CLP plasma samples (Figure [2](#F2){ref-type="fig"}). In contrast, three miRNAs, miR-1260a, miR-494--3p and miR-1304--3p, were significantly downregulated in both the CP and CLP plasma samples (Figure [2](#F2){ref-type="fig"}). Therefore, a similar pattern of upregulation and downregulation was observed in both the microarray and qRT-PCR samples for the 6 miRNAs assessed (Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Therefore, our microarray data were reliable and stable.

###### Selected six miRNAs' basic characteristics

  miRNA         Fold change in CP   Fold change in CLP   Dysregulation   miRBase deep sequencing reads
  ------------- ------------------- -------------------- --------------- -------------------------------
  miR-340-5p    4.435901            10.44386             up              329
  miR-877-5p    36.42551            38.19915             up              2840
  miR-3648      2.844126            7.529149             up              650
  miR-1260a     0.42197306          0.188688             down            29
  miR-494-3p    0.421072365         0.074374             down            153
  miR-1304-3p   0.022515879         0.021418             down            4

![Relative expression level (2^−ΔΔCt^) of miR-340-5p, miR-877-5p, miR-3648, miR-1260a, miR-494-3p, and miR-1304-3p expression in the plasma of cleft palate patients (*n* =16), cleft lip with cleft palate patients (*n* = 33) and controls (*n* = 8) (Mann-Whitney *U* test)\
*P* values are listed above the data dot.](oncotarget-07-86266-g002){#F2}

Functional analysis of potential target genes of co-expressed dysregulated miRNAs {#s2_3}
---------------------------------------------------------------------------------

To explore whether overlapping biological processes were found in both CLP and CPO, we performed gene ontology (GO) and KEGG pathway analysis for the predicted targets of the differentially expressed miRNAs, including the 63 upregulated and 49 downregulated miRNAs in both CP and CLP, which produced 4227 and 2684 predictive target genes, respectively. The top ten enriched GO terms for the upregulated and downregulated are listed in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}, respectively. The analysis revealed that the potential target genes of the 63 miRNAs upregulated in both CP and CLP were associated with glutamate secretion, aorta or palate development, positive regulation of axonogenesis, cardiac septum development, artery development, the canonical Wnt signalling pathway, and the ephrin receptor signalling pathway (Figure [3A](#F3){ref-type="fig"}). Conversely, the potential target genes of the 49 miRNAs downregulated in both CP and CLP were associated with the generation of contraction-related action potentials in cardiac muscle cells, cardiac muscle cell contraction, columnar/cuboidal epithelial cell development, cardiac conduction, positive regulation of axonogenesis, and the ephrin receptor signalling pathway (Figure [3B](#F3){ref-type="fig"}). Pathway enrichment analysis revealed that the potential target genes of the miRNAs dysregulated in both CP and CLP were involved in p53 signalling, Wnt signalling, circadian rhythm, insulin resistance, and the AMPK signalling pathway (Figure [3C, 3D](#F3){ref-type="fig"}).

![GO and KEGG pathway analyses show the associated function of the target genes of the miRNAs dysregulated in both CP and CLP\
(**A**) The top 10 enriched GO terms for the 4227 target genes of the 63 miRNAs upregulated in both CP and CLP. (**B**) The top 10 enriched GO terms for the 2684 target genes of the 49 miRNAs downregulated in both CP and CLP. (**C**) The top 30 enriched pathways for the 4227 target genes of the 63 miRNAs upregulated in both CP and CLP. (**D**) The top 30 enriched pathways for the 2684 target genes of the 49 miRNAs downregulated in both CP and CLP. (C-D) The enrichment *P* values were calculated using Fisher\'s exact test. The term/pathway on the vertical axis was drawn according to the first letter of the pathway name in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated genes)/(the number of genes in a pathway in the database/the total number of genes in the database). The top 30 enriched pathways were selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥ 4 and *p \<* 0.05. The different colours from green to red represent the *p-value*. The different sizes of the round shapes represent the gene count number in a pathway. \*indicates the pathway is similarly regulated in both CP and CLP. \# means the pathway is regulated in both CP and CLP but the miRNA target genes may be upregulated or downregulated.](oncotarget-07-86266-g003){#F3}

Function analysis of the potential target genes of the miRNAs dysregulated in CP {#s2_4}
--------------------------------------------------------------------------------

To explore whether distinct biological processes regulated CLP and CPO, we performed gene ontology (GO) and KEGG analysis of the predicted targets of the differentially expressed miRNAs in CP, including 14 upregulated miRNAs producing 1057 predictive target genes and 6 downregulated miRNAs yielding 363 potential target genes. The top ten enriched GO terms are listed in Figure [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}, respectively. The analysis revealed that the potential target genes of the 14 miRNAs upregulated in CP were associated with hippo signalling, dendrite morphogenesis or development, positive regulation of smooth muscle cell proliferation, neural tube formation and developmental cell growth (Figure [4A](#F4){ref-type="fig"}). Conversely, the potential target genes of the 6 miRNAs downregulated in CP were associated with modulation of synaptic transmission, blood vessel or tissue morphogenesis, regulation of cell morphogenesis or cell differentiation and neurogenesis (Figure [4B](#F4){ref-type="fig"}). Surprisingly, 1057 of the predictive target genes of the 14 miRNAs upregulated in CP did not display KEGG enrichment results using the SBC analysis system. For the 363 potential target genes of the 6 miRNAs downregulateCP, the pathway enrichment results showed that those genes were mainly involved in thyroid cancer, the Notch signalling pathway, fatty acid metabolism, adherens junctions and amphetamine addiction (Figure [4C](#F4){ref-type="fig"}).

![GO and KEGG pathway analyses show the associated function of the target genes of the miRNAs dysregulated in CP\
(**A**) The top 10 enriched GO terms for the 1057 target genes of the 14 miRNAs upregulated in CP. (**B**) The top 10 enriched GO terms for the 363 target genes of the 6 miRNAs downregulated in CP. (**C**) Top 30 enriched pathways for the 363 target genes of the 6 miRNAs downregulated in CP. The enrichment *P* values were calculated using Fisher\'s exact test. The term/pathway on the vertical axis was drawn according to the first letter of the pathway name in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 30 enriched pathways were selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥ 4 and *p \<* 0.05. The different colours from green to red represent the *p value*. The different sizes of the round shapes represent the gene count number in a pathway. \* indicates the pathway is similarly regulated in both CP and CLP.](oncotarget-07-86266-g004){#F4}

Function analysis of the potential target genes of the miRNAs dysregulated in CLP {#s2_5}
---------------------------------------------------------------------------------

Additionally, we performed gene ontology (GO) and KEGG analysis of the predicted targets of the differentially expressed miRNAs in CLP, including 75 upregulated miRNAs yielding 3505 possible target genes and 34 downregulated miRNAs creating 1666 possible target genes. The top ten enriched GO terms are listed in Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}, respectively. The analysis revealed that the potential target genes of the 75 miRNAs upregulated in CLP were associated with the regulation of axon extension during axon guidance, the semaphorin-plexin signalling pathway, the epidermal growth factor receptor signalling pathway, the regulation of axon extension, histone methylation and the extent of cell growth (Figure [5A](#F5){ref-type="fig"}). Conversely, the potential target genes of the 34 miRNAs downregulated in CLP were associated with glutamate secretion, the positive regulation of axon extension, multicellular organism growth, the extent of cell growth, neurotransmitter transport and the regulation of synaptic plasticity (Figure [5B](#F5){ref-type="fig"}). Pathway enrichment analysis indicated that the potential target genes of the miRNAs dysregulated in CLP were associated with specific pathways, including the thyroid hormone signalling pathway, the GnRH signalling pathway, the Hedgehog signalling pathway, and the longevity regulating pathway (Figure [5C, 5D](#F5){ref-type="fig"}).

![GO and KEGG pathway analyses show the associated function of the target genes of the miRNAs dysregulated in CLP\
(**A**) The top 10 enriched GO terms for the 3505 target genes of the 75 miRNAs upregulated in CLP. (**B**) The top 10 enriched GO terms for the 1666 target genes of the 34 miRNAs downregulated in CLP. (**C**) Top 30 enriched pathways for the 3505 target genes of the 75 miRNAs upregulated in CLP. (**D**) Top 30 enriched pathways for the 1666 target genes of the 34 miRNAs downregulated in CLP. (C--D) The enrichment *P* values were calculated using Fisher\'s exact test. The term/pathway on the vertical axis was drawn according to the first letter of the pathway name in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated genes)/(the number of genes in a pathway in the database/the total number of genes in the database). The top 30 enriched pathways were selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥ 4 and *p \<* 0.05. The different colours from green to red represent the *p value*. The different sizes of the round shapes represent the gene count number in a pathway. \* indicates the pathway is similarly regulated in both CLP and CP.](oncotarget-07-86266-g005){#F5}

DISCUSSION {#s3}
==========

Plasma miRNAs are highly stabile under handling and storage conditions \[[@R12]\]. They play crucial roles in many diseases including cancer \[[@R13], [@R14]\] and respiratory diseases \[[@R15]\]. Nonsyndromic cleft palate and nonsyndromic cleft lip with cleft palate are two types of oral clefting that occur without other developmental syndromes. Research on the roles of differentially expressed plasma miRNAs in NSCP and NSCLP patients will improve our knowledge, diagnosis and management of the two diseases. This study, for the first time, has used microarray profiling to evaluate the differential expression of miRNAs in plasma samples from NSCP and NSCLP patients compared with healthy children. Six miRNAs, namely miR-340--5p, miR-877--5p, miR-3648, miR-1260a, miR-494--3p, and miR-1304--3p, were found to be differentially expressed in both the NSCP and NSCLP plasma samples.

Venn diagrams have been widely used to visualize the relationship between complex genetic data sets \[[@R16], [@R17]\]. Based on our miRNA microarray data, we found the intersection of differentially expressed miRNAs in CP and CLP. Using Bulge-Loop™ qRT-PCR analysis, we demonstrated that the upregulated and downregulated miRNAs were consistent with the results of the miRNA microarray assay. Therefore, we investigated the key genes and pathways associated with CP and/or CLP using bioinformatics analysis according to the microarray data. In mammals, miRNAs could regulate 30% of the protein-coding genes through posttranscriptional silencing; therefore, the dysregulation of miRNAs in NSCP or NSCLP patients could have a profound influence on various biological functions.

Based on the GO analysis, the predicted target genes of the upregulated and downregulated miRNAs in both CP and CLP mainly participated in glutamate secretion, aorta or palate development, cardiac muscle cell contraction, and the ephrin receptor signalling pathway. Examining the top 30 enriched pathways showed that the target genes were solely associated with several pathways, including the AGE-RAGE signalling pathway in diabetic complications, retrograde endocannabinoid signalling, signalling pathways regulating the pluripotency of stem cells, the adipocytokine signalling pathway, arrhythmogenic right ventricular cardiomyopathy (ARVC), cocaine addiction, dilated cardiomyopathy, gastric acid secretion, glycerolipid metabolism, glycosaminoglycan biosynthesis-chondroitin sulphate/dermatan sulphate, glycosaminoglycan biosynthesis-keratan sulphate, hypertrophic cardiomyopathy (HCM), the p53 signalling pathway and mucin type O-Glycan biosynthesis. Consistent with this prediction, cleft palate and cleft lip with cleft palate may be associated with a wide range of signalling molecules, including transforming growth factors (TGFs) \[[@R18]\], bone morphogenetic proteins (BMPs) \[[@R19]\], and fibroblast growth factors (FGFs) \[[@R20]\]. In addition, various developmental transcription factors belonging to the paired box (PAX) \[[@R21]\], distal-less homeobox (DLX) \[[@R22]\], msh homeobox (MSX) \[[@R23]\], and T-Box (TBX) gene families \[[@R24]\] are also involved in CP and CLP.

Recent studies suggest that isolated cleft palate only (CPO) has independent genetic causes and should be evaluated separately \[[@R25], [@R26]\]. Therefore, we analysed the predictive target genes of nonoverlapping miRNAs in CP and CLP using GO and KEGG pathway analysis. Interestingly, the top 10 enriched GO terms showed that Hippo signalling, dendrite morphogenesis, modulation of synaptic transmission and tissue morphogenesis were related to CP. Thirteen pathways of the top 30 enriched pathways were uniquely associated with CP including 2-oxocarboxylic acid metabolism, adrenergic signalling in cardiomyocytes, breast cancer, the cAMP signalling pathway, colorectal cancer, the oestrogen signalling pathway, fatty acid metabolism, gap junctions, HTLV-I infection, the MAPK signalling pathway, pathways in cancer, the ras signalling pathway, and tight junctions. In contrast, 14 pathways of the top 30 enriched pathways were only linked with CLP including dopaminergic synapses, endocytosis, the GnRH signalling pathway, morphine addiction, non-small cell lung cancer, renin secretion, acute myeloid leukaemia, bile secretion, dorso-ventral axis formation, endometrial cancer, renal cell carcinoma, shigellosis, SNARE interactions in vesicular transport, and Sphingolipid metabolism.

NSCP and NSCLP are developmental defects. The differentially expressed plasma miRNAs identified in the affected infants could be from their mother\'s blood. Further elucidation of the sources of the plasma miRNAs in human tissues and their roles in the pathogenesis of cleft palate or cleft lip with cleft palate, particularly in palate development or the regulation of cranial neural crest (CNC) cells that give rise to craniofacial structures, needs to be further explored. In addition, larger samples are needed to perform receiver operating characteristic (ROC) curve analysis to prove that some of the children plasma microRNAs are promising biomarkers.

Taken together, based on the Bulge-Loop™ qRT-PCR analysis and miRNA microarray assay, we uncovered a differential plasma miRNA expression profile in NSCP and NSCLP patients compared with healthy children. Using GO and KEGG pathway analysis, we found distinct and overlapping biological processes or signalling pathways involved in CP and CLP. Further studies should examine the mechanism of the potential target genes, which may provide new avenues for future clinical prevention and therapy.

MATERIALS AND METHODS {#s4}
=====================

Sample collection {#s4_1}
-----------------

The study protocol was approved by the Institutional Review Board of Nanjing Medical University (2014--10--16). The plasma samples were collected according to previously described methods \[[@R11]\]. Nonsyndromic cleft palate (NSCP) and nonsyndromic cleft lip with cleft palate (NSCLP) patients who underwent surgery and healthy children (normal face but who underwent surgery for hydrocele) participated in this study with their parent\'s consent at the Department of Burns and Plastic Surgery, Nanjing Children\'s Hospital Affiliated to Nanjing Medical University in Nanjing, China. All NSCP, NSCLP and healthy children were between 2 and 12 months old. The patient information is listed in Table [4](#T4){ref-type="table"}. Briefly, peripheral blood was collected into EDTAK2 tubes (regular type), and then immediately centrifuged at 1000 g for 15 min. The supernatant plasma was transferred to RNase-free tubes and centrifuged at 12000 g for 10 min to pellet any remaining cellular debris. Aliquots of the supernatant were transferred to fresh tubes and immediately stored at --80**°**C.

###### Patient characteristics

  Group     Age (m, months; d, days)   Gender   Sample use
  --------- -------------------------- -------- ------------
  Control   9m12d                      female   Array
  Control   3m30d                      male     Array
  Control   10m                        male     Array
  Control   6m                         female   qRT-PCR
  Control   9m                         female   qRT-PCR
  Control   12m                        female   qRT-PCR
  Control   3m                         male     qRT-PCR
  Control   9m                         male     qRT-PCR
  Control   3m                         male     qRT-PCR
  Control   6m                         male     qRT-PCR
  Control   5m                         male     qRT-PCR
  CP        3m                         female   Array
  CP        6m                         female   Array
  CP        5m                         male     Array
  CP        10m7d                      female   qRT-PCR
  CP        12m                        female   qRT-PCR
  CP        3m                         female   qRT-PCR
  CP        8m28d                      female   qRT-PCR
  CP        9m20d                      female   qRT-PCR
  CP        10m9d                      female   qRT-PCR
  CP        11m13d                     female   qRT-PCR
  CP        8m                         female   qRT-PCR
  CP        12m                        female   qRT-PCR
  CP        12m                        female   qRT-PCR
  CLP       7m30d                      male     Array
  CLP       4m                         male     Array
  CLP       4m21d                      male     Array
  CLP       2m22d                      female   qRT-PCR
  CLP       4m17d                      female   qRT-PCR
  CLP       12m                        female   qRT-PCR
  CLP       10m25d                     female   qRT-PCR
  CLP       12m                        female   qRT-PCR
  CLP       10m24d                     female   qRT-PCR
  CLP       5m                         female   qRT-PCR
  CLP       7m                         female   qRT-PCR
  CLP       12m                        female   qRT-PCR
  CLP       11m                        female   qRT-PCR
  CLP       3m21d                      female   qRT-PCR
  CLP       5m30d                      female   qRT-PCR
  CLP       4m12d                      male     qRT-PCR
  CLP       3m12d                      male     qRT-PCR
  CLP       4m23d                      male     qRT-PCR
  CLP       3m20d                      male     qRT-PCR
  CLP       2m10d                      male     qRT-PCR
  CLP       2m                         male     qRT-PCR
  CLP       9m29d                      male     qRT-PCR
  CLP       12m                        male     qRT-PCR
  CLP       12m                        male     qRT-PCR
  CLP       11m3d                      male     qRT-PCR
  CLP       3m                         male     qRT-PCR
  CLP       6m                         male     qRT-PCR
  CLP       9m10d                      male     qRT-PCR
  CLP       12m                        male     qRT-PCR
  CLP       11m                        male     qRT-PCR
  CLP       4m21d                      male     qRT-PCR
  CLP       3m30d                      male     qRT-PCR
  CLP       11m12d                     male     qRT-PCR

CP, cleft palate; CLP, cleft lip with palate.

Total RNA isolation from human plasma samples {#s4_2}
---------------------------------------------

Total RNA was isolated from 400 μl of human plasma samples using the mirVana PARIS kit (Ambion, Carlsbad, CA, USA) according to the manufacturer\'s instructions. After infusing an equal volume of 2x denaturing solution to the plasma samples to inactivate RNases, the denatured samples were mixed with Synthetic Caenorhabditis elegans miRNA cel-miR-39 (GenePharma, Shanghai, China), to normalize the variation in RNA isolation from the different samples. RNA was eluted using 100 μl of elution solution.

Mature miRNA microarray analysis {#s4_3}
--------------------------------

Nine samples, which included three NSCP plasma samples (mixed as the CP group), three NSCLP plasma samples (mixed as the CLP group) and three normal plasma samples (mixed as the Control group), were analysed using Agilent human miRNA microarray chips (8\*60K) v21.0 (ShanghaiBio Corporation, Shanghai, China). The raw data were normalized using the quantile algorithm in GeneSpring Software 12.6 (Agilent Technologies, Santa Clara, CA, USA). The differentially expressed miRNAs that showed a two-fold or greater change were screened. Venn diagrams were draw online (http://bioinformatics.psb.ugent.be/webtools/Venn/).

Validation of the microarray data using Bulge-Loop™ miRNA qRT-PCR {#s4_4}
-----------------------------------------------------------------

To confirm the microarray data, six selected miRNAs with two-fold or greater changes were further validated in samples from an additional 16 CP, 33 CLP and 8 healthy children using Bulge-Loop™ qRT-PCR according to the manufacturer\'s protocol (RIBOBIO, Guangzhou, China) with SYBR green on an Applied Biosystems ViiA™ 7 Dx (Life Technologies, USA). The expression levels of the miRNAs were normalized to C. elegans control miRNA cel-39 using the 2^(--△△Ct)^ method \[[@R27]\].

Statistical analysis {#s4_5}
--------------------

The validation results from the qRT-PCR analysis are displayed as the mean ± SD. Statistical significance was assessed using the Mann-Whitney *U* test in Graphpad Prism 6 (Graphpad software, CA, USA). A *P \<* 0.05 was considered statistically significant.

GO and pathway enrichment analyses {#s4_6}
----------------------------------

The differentially expressed miRNAs were further analysed for predicted gene targets simultaneously using at least two of the following five databases: TARGETMINER, miRDB, microRNA, TarBase, and RNA22 through the ShanghaiBio Corporation (SBC) analysis system (<http://sas.ebioservice.com>). GO enrichment analyses were performed online (<http://geneontology.org/>). KEGG pathway enrichment analyses of the predicted targets of the differentially expressed miRNAs were performed according to previously described methods \[[@R11]\]. KEGG pathway enrichment analyses were performed by the ShanghaiBio Corporation (SBC) analysis system, which uses clusterProfiler data from R/bioconductor software (<http://www.r-project.org> and <http://www.bioconductor.org/>) with public databases that include NCBI Entrez Gene (<http://www.ncbi.nlm.nih.gov/gene>), GO (<http://www.geneontology.org>), KEGG (http://www.genome.jp/kegg), and Biocarta (<http://www.biocarta.com>). The enrichment *P*-values of both the GO and pathway enrichment analyses were calculated using the Fisher\'s exact test \[[@R28]\], which was corrected using enrichment *q*-values (the false discovery rate) that were calculated using John Storey\'s method \[[@R29]\].
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